1 month ago
The financial unraveling of Jon Venetos' Lurin Capital is now the subject of a Federal Bureau of Investigation probe.
An email sent to an investor from the FBI's Dallas Division shared with The Real Deal revealed that the agency has opened an investigation into Venetos, Lurin Capital and **** ociated entities. The note provided an email address through which victims can provide comments and ask questions: LurinVictimsfbi.gov.
The Real Deal also obtained a public link to an FBI form **** led "Lurin Investigation Questionnaire" seeking information from "possible victim" investors. The form asks for details about investors' contributions and any distributions received.
The company's downfall has been punctuated by claims of fraudulent dealings from lenders and former Lurin employees. Keybank accused Venetos of transferring $25,000 from his accounts with the bank to a personal account. Vista Bank accused him of falsifying account statements from the lender in an attempt to take out loans elsewhere.
In addition, a former employee who worked in property management and asked to remain anonymous claimed Lurin lied on reimbursement requests to lenders by inflating costs of repairs and submitting invoices for work that wasn't done.
#email
An email sent to an investor from the FBI's Dallas Division shared with The Real Deal revealed that the agency has opened an investigation into Venetos, Lurin Capital and **** ociated entities. The note provided an email address through which victims can provide comments and ask questions: LurinVictimsfbi.gov.
The Real Deal also obtained a public link to an FBI form **** led "Lurin Investigation Questionnaire" seeking information from "possible victim" investors. The form asks for details about investors' contributions and any distributions received.
The company's downfall has been punctuated by claims of fraudulent dealings from lenders and former Lurin employees. Keybank accused Venetos of transferring $25,000 from his accounts with the bank to a personal account. Vista Bank accused him of falsifying account statements from the lender in an attempt to take out loans elsewhere.
In addition, a former employee who worked in property management and asked to remain anonymous claimed Lurin lied on reimbursement requests to lenders by inflating costs of repairs and submitting invoices for work that wasn't done.
2 months ago
SCARDOVARI, Italy (AP) — Italian fishermen for two years incinerated most of the invasive Atlantic blue crabs caught in the Po River Delta south of Venice. Few Italians had an appetite for the alien predator blamed for decimating their prized Manila clams.
While experiments in containment continue, including the release of tens of thousands of octopus predators, the industry's response has been shifting to find new markets for the crustaceans. The strategy is already salvaging the livelihood of some fishermen and, some hope, may even rehabilitate the much-maligned crab's image in Italy.
Like other members of his local cooperative, second-generation fisherman Federico Zago saw his income crash after the crab invasion. The Polesine Fishermen's Cooperative Consortium's revenues fell 75% to 15 million euros ($17 million) in 2024 and 2025; the cooperative's active members also shrank from 1,500 to 850.
"We needed to change strategy, and create an opportunity from this disaster," said Paolo Mancin, the cooperative's president.
Desperate, they pivoted to exporting the unwanted crabs, with the aim of preserving the Manila clams — invasive themselves — and mussels that created decades of prosperity in the shallow lagoons of Veneto and Emilia Romagna.
#manila #million
While experiments in containment continue, including the release of tens of thousands of octopus predators, the industry's response has been shifting to find new markets for the crustaceans. The strategy is already salvaging the livelihood of some fishermen and, some hope, may even rehabilitate the much-maligned crab's image in Italy.
Like other members of his local cooperative, second-generation fisherman Federico Zago saw his income crash after the crab invasion. The Polesine Fishermen's Cooperative Consortium's revenues fell 75% to 15 million euros ($17 million) in 2024 and 2025; the cooperative's active members also shrank from 1,500 to 850.
"We needed to change strategy, and create an opportunity from this disaster," said Paolo Mancin, the cooperative's president.
Desperate, they pivoted to exporting the unwanted crabs, with the aim of preserving the Manila clams — invasive themselves — and mussels that created decades of prosperity in the shallow lagoons of Veneto and Emilia Romagna.
#manila #million
2 months ago
Of the eight TripAdvisor reviews of the amphitheater near Arcugnano, in Italy's northern Veneto region, all give fulsome, five-star praise.
"An enchanting place," reads one review.
"A world beyond **** e and time," enthuses another. "Definitely one of the best places I have ever been to," raves another.
"Unique on the planet," writes another visitor. That last one was prescient, because the theater certainly was unique. It wasn't Greek, as it purported to be. It wasn't even Roman.
Instead, the "kind custodian" who was "more or less a historian, and an excellent narrator," as one other visitor dubbed him, had built it himself. This month, after a 10-year legal battle, the owner has been jailed for forging works of art, carrying out building works without authorization, and destroying a protected landscape.
#visitor #wasn 't #arcugnano #veneto
"An enchanting place," reads one review.
"A world beyond **** e and time," enthuses another. "Definitely one of the best places I have ever been to," raves another.
"Unique on the planet," writes another visitor. That last one was prescient, because the theater certainly was unique. It wasn't Greek, as it purported to be. It wasn't even Roman.
Instead, the "kind custodian" who was "more or less a historian, and an excellent narrator," as one other visitor dubbed him, had built it himself. This month, after a 10-year legal battle, the owner has been jailed for forging works of art, carrying out building works without authorization, and destroying a protected landscape.
#visitor #wasn 't #arcugnano #veneto
4 months ago
Eli Lilly and Company (NYSE:LLY) is one of the high growth stocks to buy right now. On June 14, Eli Lilly announced positive results from the Phase 3 BRUIN CLL-322 clinical trial, which evaluated the addition of Jaypirca (pirtobrutinib) to a time-limited venetoclax and rituximab regimen for patients with relapsed or refractory chronic lymphocytic leukemia/CLL or small lymphocytic lymphoma/SLL. The study met its primary endpoint, showing that the pirtobrutinib combination reduced the risk of disease progression or death by 45% compared to the control arm of venetoclax and rituximab alone.
The trial enrolled 639 patients, nearly 80% of whom had been previously treated with a covalent BTK inhibitor, making the findings highly relevant to current clinical practices. At a median follow-up of 27.3 months, the median progression-free survival/PFS in the pirtobrutinib arm had not been reached, compared to 39.7 months in the control arm. These benefits were consistent across various high-risk patient subgroups, and the pirtobrutinib combination also showed a significant advantage in the time to next treatment.
The safety profile of the regimen was consistent with the known profiles of the individual medicines, with minimal additive toxicity observed when adding pirtobrutinib. Discontinuation rates due to treatment-related adverse events were similar between the two study arms. Based on these findings, Eli Lilly and Company (NYSE:LLY) plans to submit the data to global regulatory authorities with the goal of expanding the use of Jaypirca as a potential new standard of care in previously treated CLL/SLL populations.
Eli Lilly and Company (NYSE:LLY) is a healthcare company that develops human pharmaceutical products, including cardiometabolic health, oncology, and immunology products.
While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
The trial enrolled 639 patients, nearly 80% of whom had been previously treated with a covalent BTK inhibitor, making the findings highly relevant to current clinical practices. At a median follow-up of 27.3 months, the median progression-free survival/PFS in the pirtobrutinib arm had not been reached, compared to 39.7 months in the control arm. These benefits were consistent across various high-risk patient subgroups, and the pirtobrutinib combination also showed a significant advantage in the time to next treatment.
The safety profile of the regimen was consistent with the known profiles of the individual medicines, with minimal additive toxicity observed when adding pirtobrutinib. Discontinuation rates due to treatment-related adverse events were similar between the two study arms. Based on these findings, Eli Lilly and Company (NYSE:LLY) plans to submit the data to global regulatory authorities with the goal of expanding the use of Jaypirca as a potential new standard of care in previously treated CLL/SLL populations.
Eli Lilly and Company (NYSE:LLY) is a healthcare company that develops human pharmaceutical products, including cardiometabolic health, oncology, and immunology products.
While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
4 months ago
We recently compiled a list of the 10 Best Weight Loss Drug Stocks to Buy in 2026. Eli Lilly and Company (NYSE:LLY) is one of the best weight loss drugs on this list.
TheFly reported on June 16 that LLY completed the acquisition of 4E Therapeutics, a neuroscience biotechnology company based in Austin, Texas. The acquired firm is focused on developing oral MNK inhibitor therapies for chronic pain and is advancing a pipeline aimed at modulating the MNK-eIF4E signaling pathway in peripheral sensory neurons. Through the transaction, LLY expands its presence in neuroscience and pain management research. Financial details of the acquisition were not disclosed by the companies.
Separately, on June 14, Eli Lilly and Company (NYSE:LLY) reported positive results from the Phase 3 BRUIN CLL-322 study evaluating Jaypirca (pirtobrutinib) in combination with venetoclax and rituximab for patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The trial achieved its primary goal, showing that the addition of Jaypirca to a two-year venetoclax and rituximab treatment regimen lowered the risk of disease progression or death by 45% compared with venetoclax and rituximab alone. Data for overall survival, a major secondary endpoint, remain immature and will be **** sed further in future **** yses. The combination therapy also demonstrated an advantage in delaying the need for subsequent treatment, supporting its potential benefit in this patient population.
Eli Lilly and Company (NYSE:LLY) is a leading pharmaceutical company and a major player in the weight-loss market, driven by strong demand for its obesity and diabetes treatments, including Zepbound and Mounjaro.
While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
TheFly reported on June 16 that LLY completed the acquisition of 4E Therapeutics, a neuroscience biotechnology company based in Austin, Texas. The acquired firm is focused on developing oral MNK inhibitor therapies for chronic pain and is advancing a pipeline aimed at modulating the MNK-eIF4E signaling pathway in peripheral sensory neurons. Through the transaction, LLY expands its presence in neuroscience and pain management research. Financial details of the acquisition were not disclosed by the companies.
Separately, on June 14, Eli Lilly and Company (NYSE:LLY) reported positive results from the Phase 3 BRUIN CLL-322 study evaluating Jaypirca (pirtobrutinib) in combination with venetoclax and rituximab for patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The trial achieved its primary goal, showing that the addition of Jaypirca to a two-year venetoclax and rituximab treatment regimen lowered the risk of disease progression or death by 45% compared with venetoclax and rituximab alone. Data for overall survival, a major secondary endpoint, remain immature and will be **** sed further in future **** yses. The combination therapy also demonstrated an advantage in delaying the need for subsequent treatment, supporting its potential benefit in this patient population.
Eli Lilly and Company (NYSE:LLY) is a leading pharmaceutical company and a major player in the weight-loss market, driven by strong demand for its obesity and diabetes treatments, including Zepbound and Mounjaro.
While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
4 months ago
AbbVie Inc. (NYSE:ABBV) is one of the 12 High Quality Stocks to Buy for the Long Term.
On June 16, 2026, Allergan Aesthetics, an AbbVie Inc. (NYSE:ABBV) company, announced the U.S. FDA approval of Skinvive by Juvederm to reduce neck lines and improve neck appearance in adults over the age of 21. AbbVie said Skinvive by Juvederm is the first and only hyaluronic acid injectable indicated to reduce the appearance of neck wrinkles and help skin retain its natural moisture.
On June 12, 2026, AbbVie Inc. (NYSE:ABBV) announced new Phase 3 data on a fixed-duration venetoclax-based combination at the European Hematology ****** ociation 2026 Congress in Stockholm, Sweden. Final results from the Phase 3 CLL14 trial in previously untreated chronic lymphocytic leukemia showed that venetoclax plus obinutuzumab significantly improved progression-free survival compared with chlorambucil plus obinutuzumab. The nine-year ****** ysis showed long-term off-treatment efficacy and safety for the fixed-duration combination, with a median time to next treatment of 7.6 years.
After a median follow-up of 9.2 years, treatment with venetoclax plus obinutuzumab resulted in a median progression-free survival of 6.4 years, compared with 3.2 years for obinutuzumab plus chlorambucil. Last month, AbbVie also announced that the European Commission authorized an expanded label for Venclyxto to include use in combination with acalabrutinib and with ibrutinib for adult patients with previously untreated chronic lymphocytic leukemia. The authorization extends to European Union Member States, as well as Iceland, Norway, and Liechtenstein.
AbbVie Inc. (NYSE:ABBV) researches, develops, manufactures, commercializes, and sells medicines and therapies worldwide.
On June 16, 2026, Allergan Aesthetics, an AbbVie Inc. (NYSE:ABBV) company, announced the U.S. FDA approval of Skinvive by Juvederm to reduce neck lines and improve neck appearance in adults over the age of 21. AbbVie said Skinvive by Juvederm is the first and only hyaluronic acid injectable indicated to reduce the appearance of neck wrinkles and help skin retain its natural moisture.
On June 12, 2026, AbbVie Inc. (NYSE:ABBV) announced new Phase 3 data on a fixed-duration venetoclax-based combination at the European Hematology ****** ociation 2026 Congress in Stockholm, Sweden. Final results from the Phase 3 CLL14 trial in previously untreated chronic lymphocytic leukemia showed that venetoclax plus obinutuzumab significantly improved progression-free survival compared with chlorambucil plus obinutuzumab. The nine-year ****** ysis showed long-term off-treatment efficacy and safety for the fixed-duration combination, with a median time to next treatment of 7.6 years.
After a median follow-up of 9.2 years, treatment with venetoclax plus obinutuzumab resulted in a median progression-free survival of 6.4 years, compared with 3.2 years for obinutuzumab plus chlorambucil. Last month, AbbVie also announced that the European Commission authorized an expanded label for Venclyxto to include use in combination with acalabrutinib and with ibrutinib for adult patients with previously untreated chronic lymphocytic leukemia. The authorization extends to European Union Member States, as well as Iceland, Norway, and Liechtenstein.
AbbVie Inc. (NYSE:ABBV) researches, develops, manufactures, commercializes, and sells medicines and therapies worldwide.
